Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122987 · ClinicalTrials.gov registry record · Phase 4
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
A Phase 4 study of Sepsis and Septic Shock, sponsored by Kingman Regional Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06122987 is a Phase 4 study of Sepsis and Septic Shock that is actively recruiting participants, run by Kingman Regional Medical Center. The registered enrollment target is 50 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06122987, a Phase 4 study of Sepsis and Septic Shock, is actively recruiting participants, sponsored by Kingman Regional Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exists regarding the timing of initiation of these agents and there is a lack of data comparing their safety and efficacy. The current literature suggests that earlier initiation of angiotensin-II will have a more significant reduction on norepinephrine-equivalent dose compared to later initiation. In addition, approximately half of patients initiated on vasopressin do not have an early hemodynamic response 6 hours after initiation. The purpose of this study is to evaluate the efficacy of angiotensin-II when used as the second vasopressor agent for septic shock.
Conditions Studied
Interventions
- DRUG Angiotensin II and hydrocortisone sodium succinate
Study Locations (1)
Arizona
- Kingman Regional Medical Center - Kingman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2025-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06122987
The ClinicalTrials.gov registry entry for NCT06122987 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The listed sponsor is Kingman Regional Medical Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II and hydrocortisone sodium succinate is the first listed.
NCT06122987 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06122987 about?
NCT06122987 is a clinical study titled "Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock". Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exi...
What is the current status of trial NCT06122987?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-12-04. Estimated completion is 2025-01.
What conditions does trial NCT06122987 study?
This clinical trial studies the following conditions: Sepsis, Septic Shock, Shock, Systemic Inflammatory Response Syndrome.
What interventions are being tested in trial NCT06122987?
The interventions under investigation include: Angiotensin II and hydrocortisone sodium succinate (DRUG).
Who is sponsoring clinical trial NCT06122987?
This trial is sponsored by Kingman Regional Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122987 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
The PASTDUe Nutrition Ecosystem Project (PASTDUe)
ACTIVE NOT RECRUITING · Phase 4
-
Effect of Nebulized Bronchodilators on Heart Rate
COMPLETED · Phase 4
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.